AngioDynamics, Inc. announced expanded European indications for its NanoKnife system with irreversible electroporation (IRE) ...

Scientists have identified a hidden barrier that prevents immunotherapy from working against a rare liver cancer. Immunotherapy, which activates the body’s own immune system to kill cancer cells, has ...

PLT012 received FDA fast track status for liver cancer, with an ongoing trial evaluating safety and early activity of the CD36-targeting immunotherapy.

Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed a score that predicts the risk of liver cancer. Published in the journal Proceedings ...

The University of Missouri and MU Health Care recently started a first round of in-person trials of a new cancer treatment.

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...

MU has launched its first clinical trial using reactor-made Eye90 microspheres to target inoperable liver tumors with ...

A research team at the University of Missouri has treated the first cancer patient with a new nuclear medicine device that targets tumors inside the liver. The early-stage clinical trial focuses on ...

The University of Missouri (Mizzou) in the US has reached a major milestone in ...